Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/94776
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Calmodulin levels in blood cells as a potential biomarker of Alzheimer's disease |
Autor: | Esteras, Noemí CSIC ORCID; Alquézar, Carolina CSIC ORCID; De la Encarnación, Ana CSIC ORCID; Villarejo, Alberto; Bermejo-Pareja, Félix; Martín-Requero, Ángeles CSIC ORCID | Fecha de publicación: | 7-nov-2013 | Citación: | Alzheimer's Research & Therapy 5(6):55 (2013) | Resumen: | Abstract Introduction The clinical features of Alzheimer’s disease (AD) overlap with a number of other dementias and conclusive diagnosis is only achieved at autopsy. Accurate in-life diagnosis requires finding biomarkers suitable for early diagnosis, as well as for discrimination from other types of dementia. Mounting evidence suggests that AD-dependent processes may also affect peripheral cells. We previously reported that calmodulin (CaM) signaling is impaired in AD lymphoblasts. Here, we address the issue as to whether the assessment of CaM levels in peripheral cells could serve as a diagnostic biomarker. Methods A total of 165 subjects were enrolled in the study, including 56 AD patients, 15 patients with mild cognitive impairment, 7 with frontotemporal dementia associated with progranulin mutations, 4 with dementia with Lewy bodies, 20 patients with Parkinson’s disease, 10 with amyotrophic lateral sclerosis, 5 with progressive supranuclear palsy, and 48 cognitively normal individuals. CaM levels were then analyzed in lymphoblasts, peripheral blood mononuclear cells and plasma. Receiver operating characteristic (ROC) curve analyses were employed to evaluate the diagnostic performance of CaM content in identifying AD patients. Results Compared with control individuals, CaM levels were significantly increased in AD cells, but not in the other neurodegenerative disorders. CaM levels differentiated AD from control with a sensitivity of 0.89 and a specificity of 0.82 and were not dependent on disease severity or age. MCI patients also showed higher levels of the protein. Conclusions CaM levels could be considered a peripheral biomarker for AD in its early stage and help to discriminate from other types of dementia. | Versión del editor: | http://dx.doi.org/10.1186/alzrt219 | URI: | http://hdl.handle.net/10261/94776 | DOI: | 10.1186/alzrt219 | E-ISSN: | 1758-9193 |
Aparece en las colecciones: | (CIB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
alzrt219.xml | 87,96 kB | XML | Visualizar/Abrir | |
ALZRT219-S1.DOCX | 98,43 kB | Microsoft Word XML | Visualizar/Abrir | |
alzrt219.pdf | 786,21 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
8
checked on 19-abr-2024
SCOPUSTM
Citations
22
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
21
checked on 26-feb-2024
Page view(s)
400
checked on 23-abr-2024
Download(s)
470
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.